Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."

You may also be interested in...



Epizyme Builds A Cancer Company At Mach Speed

Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.

Related Content

Topics

UsernamePublicRestriction

Register

PS065485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel